EUVIMEDEUVIMED entdecken
Crossref

Proteasome Inhibition Induces IRF1 Downstream Molecules Independently of JAK Activity in Cancers

Kaito Takahashi, Atsushi Takahashi, Nana Takahashi, Yue Zhou, Hiroaki Sakurai, Satoru Yokoyama

Biological and Pharmaceutical Bulletin · 2025

DOI: 10.1248/bpb.b25-00006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2025. Verfasst von Kaito Takahashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. Hauptthemen laut MEDLINE: Interferon Regulatory Factor-1, Proteasome Inhibitors, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loss-of-function mutations in Janus kinase 1/2 (JAK1/2) cause low tumor immunogenicity through defects in the induction of the transcription factor interferon regulatory factor 1 (IRF1), resulting in non-responsiveness to cancer immunotherapy reagents. Therefore, the discovery of reagents that increase IRF1 expression independent of JAK activity is clinically important for the success of cancer immunotherapy reagents. We herein demonstrated that proteasome inhibitors activated IRF1 downstream pathways in a JAK-independent manner in various cancer types. Proteasome inhibitors increased IRF1 expression by inhibiting the degradation of IRF1 in melanoma. Furthermore, proteasome inhibitors induced the expression of the IRF1 downstream molecules, programmed death-ligand 1 (PD-L1), PD-L2, and human leukocyte antigen class I molecules. The induction of IRF1 expression by proteasome inhibitors was also detected in cancer types other than melanoma. Moreover, we showed that the induction of IRF1 expression was independent of JAK activity by genetic or chemical inhibition of JAK. Therefore, proteasome inhibitors may serve as adjuvants that potentiate the efficacy of cancer immunotherapy reagents by enhancing cancer immunogenicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon Regulatory Factor-1Proteasome InhibitorsNeoplasmsHumansCell Line, TumorAnimalsB7-H1 AntigenJanus Kinase 1Janus Kinase 2

Stichwörter der Autor:innen

immune checkpoint inhibitorinterferon regulatory factor 1programmed death-ligand 1proteasome inhibitor

Substanzen

Interferon Regulatory Factor-1IRF1 protein, humanProteasome InhibitorsB7-H1 AntigenJanus Kinase 1JAK1 protein, humanCD274 protein, humanJanus Kinase 2

Autor:innen und Institutionen

  • Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.

Zitieren

APA

Takahashi, K., Takahashi, A., Takahashi, N., Zhou, Y., Sakurai, H., & Yokoyama, S. (2025). Proteasome Inhibition Induces IRF1 Downstream Molecules Independently of JAK Activity in Cancers. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b25-00006

Vancouver

Takahashi K, Takahashi A, Takahashi N, Zhou Y, Sakurai H, Yokoyama S. Proteasome Inhibition Induces IRF1 Downstream Molecules Independently of JAK Activity in Cancers. Biological and Pharmaceutical Bulletin. 2025. doi:10.1248/bpb.b25-00006

BibTeX
@article{Takahashi2025,
  author = {Takahashi, Kaito and Takahashi, Atsushi and Takahashi, Nana and Zhou, Yue and Sakurai, Hiroaki and Yokoyama, Satoru},
  title = {Proteasome Inhibition Induces IRF1 Downstream Molecules Independently of JAK Activity in Cancers},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2025},
  doi = {10.1248/bpb.b25-00006}
}
Kostenlos starten →